Literature DB >> 31237618

Female-Specific Role of Progranulin to Suppress Bone Formation.

Liping Wang1,2, Theresa Roth1, Mary C Nakamura2,3, Robert A Nissenson1,2.   

Abstract

Progranulin (PGRN) is best known as a glial protein for which deficiency leads to the most common inherited form of frontotemporal dementia. Recently, PGRN has been found to be an adipokine associated with diet-induced obesity and insulin resistance. Therefore, PGRN may have homeostatic effects on bone because PGRN is reported to promote the differentiation of bone-resorbing osteoclasts. We investigated the actions of PGRN on bone using PGRN gene (Grn) knockout (KO) mice and transgenic mice with PGRN mutation and surprisingly found that loss of PGRN prevented the bone loss in female mice induced by aging and estrogen deficiency, whereas it had no effect on male bones during aging. Strikingly, bone formation was increased in female (but not male) PGRN KO mice. We also found that loss of PGRN inhibited bone resorption and osteoclastogenesis in both male and female mice and promoted the production of osteogenic factors in osteoclast lineage cells. These results indicate that PGRN serves to uncouple bone turnover in female mice by promoting bone resorption and suppressing bone formation. Furthermore, we demonstrated that microglial cells/macrophages, but not adipocytes, are an important source of PGRN in producing negative skeletal effects in females. Targeting PGRN production by microglial cells/macrophage-lineage cells may provide a therapeutic approach for the treatment of osteoporosis in females.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31237618      PMCID: PMC6691684          DOI: 10.1210/en.2018-00842

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  40 in total

Review 1.  Real-time PCR quantification of precursor and mature microRNA.

Authors:  Thomas D Schmittgen; Eun Joo Lee; Jinmai Jiang; Anasuya Sarkar; Liuqing Yang; Terry S Elton; Caifu Chen
Journal:  Methods       Date:  2008-01       Impact factor: 3.608

2.  Clinical issues with bisphosphonate therapy for osteoporosis. Introduction.

Authors:  Ethel S Siris
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

Review 3.  Osteoblasts: novel roles in orchestration of skeletal architecture.

Authors:  E J Mackie
Journal:  Int J Biochem Cell Biol       Date:  2003-09       Impact factor: 5.085

4.  Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis.

Authors:  Jian Q Feng; Feng-Jin Guo; Bai-Chun Jiang; Yan Zhang; Sally Frenkel; Da-Wei Wang; Wei Tang; Yixia Xie; Chuan-Ju Liu
Journal:  FASEB J       Date:  2010-02-02       Impact factor: 5.191

5.  PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue.

Authors:  Toshiya Matsubara; Ayako Mita; Kohtaro Minami; Tetsuya Hosooka; Sohei Kitazawa; Kenichi Takahashi; Yoshikazu Tamori; Norihide Yokoi; Makoto Watanabe; Ei-Ichi Matsuo; Osamu Nishimura; Susumu Seino
Journal:  Cell Metab       Date:  2012-01-04       Impact factor: 27.287

6.  Short-Term Effect of Estrogen on Human Bone Marrow Fat.

Authors:  Eelkje J Limonard; Annegreet G Veldhuis-Vlug; Laura van Dussen; Jurgen H Runge; Michael W Tanck; Erik Endert; Annemieke C Heijboer; Eric Fliers; Carla E Hollak; Erik M Akkerman; Peter H Bisschop
Journal:  J Bone Miner Res       Date:  2015-07-14       Impact factor: 6.741

7.  Increased bone mass in mice lacking the adipokine apelin.

Authors:  Lalita Wattanachanya; Wei-Dar Lu; Ramendra K Kundu; Liping Wang; Marcia J Abbott; Dylan O'Carroll; Thomas Quertermous; Robert A Nissenson
Journal:  Endocrinology       Date:  2013-04-12       Impact factor: 4.736

Review 8.  Progranulin: at the interface of neurodegenerative and metabolic diseases.

Authors:  Andrew D Nguyen; Thi A Nguyen; Lauren Herl Martens; Laura L Mitic; Robert V Farese
Journal:  Trends Endocrinol Metab       Date:  2013-09-10       Impact factor: 12.015

9.  Cyclic AMP signaling in bone marrow stromal cells has reciprocal effects on the ability of mesenchymal stem cells to differentiate into mature osteoblasts versus mature adipocytes.

Authors:  Richard Kao; Weidar Lu; Alyssa Louie; Robert Nissenson
Journal:  Endocrine       Date:  2012-06-14       Impact factor: 3.633

10.  Estrogen signaling in arcuate Kiss1 neurons suppresses a sex-dependent female circuit promoting dense strong bones.

Authors:  Candice B Herber; William C Krause; Liping Wang; James R Bayrer; Alfred Li; Matthew Schmitz; Aaron Fields; Breanna Ford; Zhi Zhang; Michelle S Reid; Daniel K Nomura; Robert A Nissenson; Stephanie M Correa; Holly A Ingraham
Journal:  Nat Commun       Date:  2019-01-11       Impact factor: 14.919

View more
  3 in total

1.  Progranulin, a moderator of estrogen/estrogen receptor α binding, regulates bone homeostasis through PERK/p-eIF2 signaling pathway.

Authors:  Yuyou Yang; Naibo Feng; Li Liang; Rong Jiang; Yiming Pan; Nana Geng; Mengtian Fan; Xiaoli Li; Fengjin Guo
Journal:  J Mol Med (Berl)       Date:  2022-07-15       Impact factor: 5.606

2.  Gene Expression and RNA Splicing Imputation Identifies Novel Candidate Genes Associated with Osteoporosis.

Authors:  Yong Liu; Hui Shen; Jonathan Greenbaum; Anqi Liu; Kuan-Jui Su; Li-Shu Zhang; Lei Zhang; Qing Tian; Hong-Gang Hu; Jin-Sheng He; Hong-Wen Deng
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

3.  Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice.

Authors:  Zamzam Awida; Sahar Hiram-Bab; Almog Bachar; Hussam Saed; Dan Zyc; Anton Gorodov; Nathalie Ben-Califa; Sewar Omari; Jana Omar; Liana Younis; Jennifer Ana Iden; Liad Graniewitz Visacovsky; Ida Gluzman; Tamar Liron; Bitya Raphael-Mizrahi; Albert Kolomansky; Martina Rauner; Ben Wielockx; Yankel Gabet; Drorit Neumann
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.